Saturday, 31 October 2026European Markets

Cosmetics Company Experiences 17% Increase In Stock Price Over Past Five Sessions

Loading stream...

(vianews) - shares of augros cosmetics (cac 40: augr.pa) experienced an extraordinary surge, increasing 17.29% from eur6.65 to eur7.80 within five sessions - marking a dramatic turnaround following two consecutive losses and one day of gains - at 16:05 est on tuesday afternoon, marking a substantial rebound following two straight sessions of losses. meanwhile, cac 40 index members including augros cosmetics also enjoyed gains, rising by 0.15% to eur7,335.46, following two consecutive increases. the sudden spike may have been due to positive news or developments within augros cosmetics although exact reasons behind it remain unknown at present.

about augros cosmetics

augros cosmetic packaging sa is a leading provider of tailored packaging solutions in france, specializing in decorative solutions for glass, plastic and aluminum packaging materials. augros' innovative offerings have become a favorite choice of perfumers, cosmeticians and spirits producers across these industries. headquartered in alencon with subsidiary famille bourgine as its parent organization.

technical analysis

augros cosmetics (augros) has seen its volume significantly decline with today's reported volume at 14 representing 72.97% less than its average volume of 74. this drop could indicate lack of investor enthusiasm or temporary reduced trading activity. as far as volatility goes, augros has experienced mild fluctuations in its prices over recent weeks, months, and quarters. its intraday variation average for the past week, month, and quarter respectively has been 8.59%; last month was 0.20; while highest amplitude average volatility for augros over this timeframe has been 8.57 (week), 8.07 (7 month), and 0.808 (8 quarter). additionally, augros has been identified by the stochastic oscillator as being oversold - this could suggest undervaluation and potential for rebound. conclusion: at present, augros cosmetics is experiencing low trading volume, moderate volatility, and an oversold classification according to its stochastic oscillator - all factors which could account for its recent downward price trend. investors should pay close attention to these indicators along with any relevant news or events in order to make informed decisions regarding augros investments.

equity analysis

based on available data, augros cosmetics currently boasts a trailing twelve months eps of eur0.43 and an earnings-price ratio of 18.14; meaning investors are paying eur18.14 for every euro of annual earnings. as an indicator of investment outlook, pe ratio can provide some useful insight. a higher pe ratio may indicate investors have high hopes for future earnings growth while lower pe ratios suggest they have lower expectations; it's also important to take other factors such as company finances, competitive position and industry trends into account before making an investment decision. compare augros cosmetics' pe ratio against that of its peers and the wider market to assess how it measures up. investors may also wish to take into account factors like revenue growth, profit margins and debt levels when evaluating its investment potential.

more news about augros cosmetics (augr.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,514 source documents archived
Query this data → isubstrate.com